Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Cardiology

Genotype-Driven Treatment Strategies

At a Glance

Treatment for Long QT Syndrome is highly personalized based on your specific genetic type. While daily non-selective beta-blockers like Nadolol are the primary shield for most patients, others may need targeted medications like Mexiletine, LCSD surgery, or an ICD device for ultimate protection.

Treatment for Long QT Syndrome (LQTS) is not one-size-fits-all. Because the underlying cause—the “jammed door” or “leaky faucet”—is different for each genotype, your medical team will tailor your treatment to match your specific genetic profile [1][2]. The goal of treatment is to stabilize the heart’s electrical timing and prevent dangerous rhythms [3].

The Shield: Beta-Blockers

Beta-blockers are the foundation of treatment for almost everyone with LQTS, especially those with LQT1 and LQT2 [4][3]. They act like a “shield” that prevents adrenaline from triggering an unstable heart rhythm [1].

  • Non-Selective is Key: Doctors typically prefer “non-selective” beta-blockers like Nadolol or Propranolol [4][5].
  • The Gold Standard (Nadolol): Nadolol is often considered the best choice because it stays in the system longer (allowing for once-a-day dosing) and has been shown to be more effective at preventing cardiac events than “selective” beta-blockers like metoprolol or atenolol [4][5].
  • LQT3 Caveat: For LQT3, beta-blockers are used very carefully. Because LQT3 events happen when the heart is beating slowly (like during sleep), lowering the heart rate too much with beta-blockers can actually trigger an event [1].

The Realities of Beta-Blockers

Calling medication a “shield” is accurate, but it is important to be honest about the realities of taking it every day.

  • Side Effects and Adjustment: When starting beta-blockers, many patients experience profound fatigue, vivid dreams, or a significantly reduced ability to exercise. Fortunately, your body often adapts over a few weeks or months, and many of these side effects improve [6].
  • The Golden Rule—Never Stop Abruptly: You must never suddenly stop taking your beta-blocker. Missing doses or abruptly quitting causes a “rebound effect,” where the heart becomes dangerously over-sensitive to adrenaline, severely increasing the risk of a life-threatening arrhythmia [7].

The Specialized Fix: Mexiletine for LQT3

In LQT3, the problem isn’t just sensitivity to adrenaline; it’s a sodium channel that stays open too long (the “leaky faucet”) [8][9].

  • Mexiletine is a medication that specifically targets and blocks these leaky sodium channels [10][11].
  • By closing the “leak,” mexiletine can actually shorten the QTc interval, making the heart’s electrical reset more normal [12][13].
  • LQT3 patients are often treated with a combination of a beta-blocker and mexiletine for dual protection [1][14].

Surgical Support: LCSD

If medications are not enough, or if a patient cannot tolerate them, a surgery called Left Cardiac Sympathetic Denervation (LCSD) may be considered [15][16].

  • How it works: Surgeons remove specific nerves on the left side of the chest that send “stress” signals to the heart [17][18].
  • The result: By “cutting the wires” of the stress signal, the heart becomes much more stable and less likely to enter a dangerous rhythm [19][20].
  • LCSD is often used as a “bridge” to avoid or delay the need for an ICD in children [19].

The Safety Net: The ICD

An Implantable Cardioverter-Defibrillator (ICD) is a small device placed under the skin that monitors the heart 24/7 [21].

  • Secondary Prevention: If a person has already survived a cardiac arrest, an ICD is almost always recommended to prevent a future event [22][21].
  • Primary Prevention: For those who haven’t had a major event but are at very high risk (due to extremely long QT intervals or symptoms that persist despite medication), an ICD provides a “safety net” that can shock the heart back into a normal rhythm if a dangerous event occurs [21][22].

Every treatment plan requires shared decision-making between you and your cardiologist to balance safety, activity levels, and quality of life [23].

Common questions in this guide

Which beta-blockers are best for Long QT Syndrome?
Doctors typically prefer non-selective beta-blockers like Nadolol or Propranolol for LQTS. Nadolol is often considered the gold standard because it stays in your system longer, allowing for once-a-day dosing, and is highly effective at preventing cardiac events.
Why is Mexiletine used for LQT3?
In LQT3, the condition is driven by sodium channels in the heart that stay open too long. Mexiletine is a specialized medication that targets and blocks these leaky sodium channels, helping to normalize the heart's electrical reset.
What happens if I miss a dose of my LQTS beta-blocker?
You should never suddenly stop taking your beta-blocker or miss doses. Doing so causes a dangerous rebound effect where the heart becomes extremely sensitive to adrenaline, severely increasing the risk of a life-threatening arrhythmia.
What is LCSD surgery for Long QT Syndrome?
Left Cardiac Sympathetic Denervation (LCSD) is a surgery where doctors remove specific nerves in the chest that send stress signals to the heart. This 'cuts the wires' of the stress signal, making the heart much more stable and reducing the chance of dangerous rhythms.
When is an ICD recommended for LQTS?
An Implantable Cardioverter-Defibrillator (ICD) is a safety net device placed under the skin. It is typically recommended for patients who have survived a cardiac arrest, or those at very high risk for severe events who cannot be fully protected by medication alone.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which specific beta-blocker is best for my child's genotype? Is Nadolol an option given its long-acting nature?
  2. 2.If my child has LQT3, should we be adding Mexiletine to their treatment plan?
  3. 3.What are the criteria for considering Left Cardiac Sympathetic Denervation (LCSD) if medications aren't fully managing the symptoms?
  4. 4.At what point does an ICD become the recommended step for my child?
  5. 5.How should we manage the expected side effects of starting a beta-blocker?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (23)
  1. 1

    Mexiletine Treatment for Neonatal LQT3 Syndrome: Case Report and Literature Review.

    Bagkaki A, Tsoutsinos A, Hatzidaki E, et al.

    Frontiers in pediatrics 2021; (9()):674041 doi:10.3389/fped.2021.674041.

    PMID: 34504812
  2. 2

    Molecular Pathophysiology of Congenital Long QT Syndrome.

    Bohnen MS, Peng G, Robey SH, et al.

    Physiological reviews 2017; (97(1)):89-134 doi:10.1152/physrev.00008.2016.

    PMID: 27807201
  3. 3

    Indications for mexiletine in the new ESC guidelines and beyond.

    Vamos M, Zsigmond EJ, Hohnloser SH

    Expert opinion on pharmacotherapy 2023; (24(12)):1403-1407 doi:10.1080/14656566.2023.2223964.

    PMID: 37306465
  4. 4

    Excellent response to β-1 adrenergic receptor blockade (metoprolol) and exercise restriction in high-risk type 1 long QT syndrome. A 22-year follow-up.

    Tejeda-Mollinedo W, Díaz-Tostado S, Gómez-Flores J, et al.

    HeartRhythm case reports 2022; (8(3)):191-194 doi:10.1016/j.hrcr.2021.12.006.

    PMID: 35492848
  5. 5

    Different beta-blockers for preventing arrhythmic events in patients with long QT syndrome: a network meta-analysis.

    Jiang Y, Zhang L, Xiong H, et al.

    Frontiers in medicine 2025; (12()):1730755 doi:10.3389/fmed.2025.1730755.

    PMID: 41476885
  6. 6

    Clinical and genetic profile of congenital long QT syndrome in Hong Kong: a 20-year experience in paediatrics.

    Kwok SY, Liu AP, Chan CY, et al.

    Hong Kong medical journal = Xianggang yi xue za zhi 2018; (24(6)):561-570 doi:10.12809/hkmj187487.

    PMID: 30530868
  7. 7

    Effectiveness of beta-blockers depending on the genotype of congenital long-QT syndrome: A meta-analysis.

    Ahn J, Kim HJ, Choi JI, et al.

    PloS one 2017; (12(10)):e0185680 doi:10.1371/journal.pone.0185680.

    PMID: 29059199
  8. 8

    Structures Illuminate Cardiac Ion Channel Functions in Health and in Long QT Syndrome.

    Brewer KR, Kuenze G, Vanoye CG, et al.

    Frontiers in pharmacology 2020; (11()):550 doi:10.3389/fphar.2020.00550.

    PMID: 32431610
  9. 9

    Induced Pluripotent Stem Cell-Derived Cardiomyocytes with SCN5A R1623Q Mutation Associated with Severe Long QT Syndrome in Fetuses and Neonates Recapitulates Pathophysiological Phenotypes.

    Hayama E, Furutani Y, Kawaguchi N, et al.

    Biology 2021; (10(10)) doi:10.3390/biology10101062.

    PMID: 34681161
  10. 10

    Pronounced Shortening of QT Interval With Mexiletine Infusion Test in Patients With Type 3 Congenital Long QT Syndrome.

    Funasako M, Aiba T, Ishibashi K, et al.

    Circulation journal : official journal of the Japanese Circulation Society 2016; (80(2)):340-5 doi:10.1253/circj.CJ-15-0984.

    PMID: 26632536
  11. 11

    The role of mexiletine in the management of long QT syndrome.

    Li G, Zhang L

    Journal of electrocardiology 2018; (51(6)):1061-1065 doi:10.1016/j.jelectrocard.2018.08.035.

    PMID: 30497731
  12. 12

    Gene-Specific Therapy With Mexiletine Reduces Arrhythmic Events in Patients With Long QT Syndrome Type 3.

    Mazzanti A, Maragna R, Faragli A, et al.

    Journal of the American College of Cardiology 2016; (67(9)):1053-1058 doi:10.1016/j.jacc.2015.12.033.

    PMID: 26940925
  13. 13

    Mechanisms underlying age-associated manifestation of cardiac sodium channel gain-of-function.

    Nowak MB, Poelzing S, Weinberg SH

    Journal of molecular and cellular cardiology 2021; (153()):60-71 doi:10.1016/j.yjmcc.2020.12.008.

    PMID: 33373643
  14. 14

    Effectiveness and safety of mexiletine in patients at risk for (recurrent) ventricular arrhythmias: a systematic review.

    van der Ree MH, van Dussen L, Rosenberg N, et al.

    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2022; (24(11)):1809-1823 doi:10.1093/europace/euac087.

    PMID: 36036670
  15. 15

    Optimizing Peri-Operative Pain Management in Children With Long QT Syndrome and Catecholaminergic Polymorphic Ventricular Tachycardia Undergoing Left Cardiac Sympathetic Denervation: A Case Series on Continuous Erector Spinae Plane Block and Serratus Plane Block.

    Mossetti V, Di Corrado R, HaxhiNasto H, et al.

    Paediatric anaesthesia 2026; (36(2)):173-180 doi:10.1111/pan.70075.

    PMID: 41195781
  16. 16

    Video-thoracoscopic left cardiac sympathetic denervation for long-QT syndrome.

    Lampridis S, Antonopoulos A, Kakos C, et al.

    Asian cardiovascular & thoracic annals 2021; (29(3)):186-190 doi:10.1177/0218492320971492.

    PMID: 33115260
  17. 17

    Left cardiac sympathetic denervation reduces skin sympathetic nerve activity in patients with long QT syndrome.

    Han J, Ackerman MJ, Moir C, et al.

    Heart rhythm 2020; (17(10)):1639-1645 doi:10.1016/j.hrthm.2020.03.023.

    PMID: 32276050
  18. 18

    Inhibition of Satellite Glial Cell Activation in Stellate Ganglia Prevents Ventricular Arrhythmogenesis and Remodeling After Myocardial Infarction.

    Zhou Z, Zhang H, Xiong H, et al.

    Circulation. Arrhythmia and electrophysiology 2025; (18(10)):e013866 doi:10.1161/CIRCEP.125.013866.

    PMID: 41025235
  19. 19

    Left cardiac sympathetic denervation in the management of long QT syndrome and catecholaminergic polymorphic ventricular tachycardia: A meta-regression.

    Sgrò A, Drake TM, Lopez-Ayala P, Phan K

    Congenital heart disease 2019; (14(6)):1102-1112 doi:10.1111/chd.12855.

    PMID: 31621201
  20. 20

    Left cardiac sympathetic denervation: An important treatment option for patients with hereditary ventricular arrhythmias.

    Cho Y

    Journal of arrhythmia 2016; (32(5)):340-343 doi:10.1016/j.joa.2015.08.002.

    PMID: 27761156
  21. 21

    Congenital Long QT Syndrome.

    Krahn AD, Laksman Z, Sy RW, et al.

    JACC. Clinical electrophysiology 2022; (8(5)):687-706 doi:10.1016/j.jacep.2022.02.017.

    PMID: 35589186
  22. 22

    Management of Patients with Long QT Syndrome.

    Cho Y

    Korean circulation journal 2016; (46(6)):747-752 doi:10.4070/kcj.2016.46.6.747.

    PMID: 27826330
  23. 23

    Long-QT Syndrome and Competitive Sports.

    Schnell F, Behar N, Carré F

    Arrhythmia & electrophysiology review 2018; (7(3)):187-192 doi:10.15420/aer.2018.39.3.

    PMID: 30416732

This page explains general treatment strategies for Long QT Syndrome for educational purposes only. Always consult your pediatric cardiologist or electrophysiologist before starting, stopping, or changing any heart medications.

Get notified when new evidence is published on Congenital long QT syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.